EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toward the Development of a Pan-Lyssavirus Vaccine

Sabrine Ben Hamed, Jacob F Myers iD, Anisha Chandwani, Christoph Wirblich, Drishya Kurup iD, Nir Paran iD, Matthias J Schnell iD

Viruses · 2024

DOI: 10.3390/v16071107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Sabrine Ben Hamed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: Lyssavirus, Antibodies, Viral, Rabies virus, Rabies Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH/NIAID, National Institute of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In addition to the rabies virus (RABV), 16 more lyssavirus species have been identified worldwide, causing a disease similar to RABV. Non-rabies-related human deaths have been described, but the number of cases is unknown, and the potential of such lyssaviruses causing human disease is unpredictable. The current rabies vaccine does not protect against divergent lyssaviruses such as Mokola virus (MOKV) or Lagos bat virus (LBV). Thus, a more broad pan-lyssavirus vaccine is needed. Here, we evaluate a novel lyssavirus vaccine with an attenuated RABV vector harboring a chimeric RABV glycoprotein (G) in which the antigenic site I of MOKV replaces the authentic site of rabies virus (RABVG-cAS1). The recombinant vaccine was utilized to immunize mice and analyze the immune response compared to homologous vaccines. Our findings indicate that the vaccine RABVG-cAS1 was immunogenic and induced high antibody titers against both RABVG and MOKVG. Challenge studies with different lyssaviruses showed that replacing a single antigenic site of RABV G with the corresponding site of MOKV G provides a significant improvement over the homologous RABV vaccine and protects against RABV, Irkut virus (IRKV), and MOKV. This strategy of epitope chimerization paves the way towards a pan-lyssavirus vaccine to safely combat the diseases caused by these viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LyssavirusAntibodies, ViralRabies virusRabies VaccinesRabiesAnimalsMiceRhabdoviridae InfectionsVaccines, SyntheticFemaleViral VaccinesGlycoproteinsAntibodies, NeutralizingVaccine DevelopmentHumansAntigens, ViralMice, Inbred BALB C

Stichwörter der Autor:innen

Irkut virusMokola virusepitope-based vaccinelyssaviruspan-lyssavirus vaccinerabies virus

Substanzen

Antibodies, ViralRabies VaccinesVaccines, SyntheticViral VaccinesGlycoproteinsAntibodies, NeutralizingAntigens, Viral

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.

ORCID-Profile: Jacob F Myers, Drishya Kurup, Nir Paran, Matthias J Schnell

Förderung

  • NIH/NIAID
  • National Institute of Health (NIH)

Zitieren

APA

Ben Hamed, S., Myers, J. F., Chandwani, A., Wirblich, C., Kurup, D., Paran, N., & Schnell, M. J. (2024). Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. https://doi.org/10.3390/v16071107

Vancouver

Ben Hamed S, Myers JF, Chandwani A, Wirblich C, Kurup D, Paran N, et al. Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. 2024. doi:10.3390/v16071107

BibTeX
@article{BenHamed2024,
  author = {Ben Hamed, Sabrine and Myers, Jacob F and Chandwani, Anisha and Wirblich, Christoph and Kurup, Drishya and Paran, Nir and Schnell, Matthias J},
  title = {Toward the Development of a Pan-Lyssavirus Vaccine},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16071107}
}
Kostenlos starten →